Neoprobe Corporation Becomes Navidea Biopharmaceuticals
05 Januar 2012 - 2:30PM
Business Wire
Neoprobe Corporation (NEOP) today announced that it has
completed its corporate name change to Navidea Biopharmaceuticals,
Inc. (NYSE Amex: NAVB). The Company will begin trading under the
ticker symbol, NAVB, on the NYSE Amex at market open today. The
CUSIP number for NAVB common stock has also been changed to
63937X103.
The Navidea name and logo represent the Company’s dedication to
“NAVigating IDEAs” that translate cutting edge innovation and
precision diagnostics technology into novel products to advance
patient care.
Navidea’s website is expected to be launched in the coming days
and may be found at www.navidea.com.
About Navidea Biopharmaceuticals
Navidea Biopharmaceuticals (NYSE Amex: NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision diagnostics and radiopharmaceutical
agents. Navidea is actively developing three radiopharmaceutical
agent platforms – Lymphoseek®, AZD4694 and RIGScanTM – to help
identify the presence and status of disease and enable better
diagnostic accuracy, clinical decision-making and ultimately
patient care. Navidea’s strategy is to deliver superior growth and
shareholder return by bringing to market novel radiopharmaceutical
agents and advancing the Company’s pipeline through selective
acquisitions, global partnering and commercialization efforts. For
more information, please visit www.navidea.com.
Neoprobe Corp. Common Stock (AMEX:NEOP)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Neoprobe Corp. Common Stock (AMEX:NEOP)
Historical Stock Chart
Von Sep 2023 bis Sep 2024
Echtzeit-Nachrichten über Neoprobe Corp. Common Stock (Amerikanische Börse): 0 Nachrichtenartikel
Weitere Neoprobe Corporation and Navidea Biopharmaceuticals, Inc. News-Artikel